Episode summary
Friday's First Moves: MRNA Cancer Vaccine Trial Leaks, DECK Earnings, NCLH Downgrade
Summary
Moderna sold off after a leak of late-stage cancer vaccine data reinforced expectations that were already extremely high. The host said the stock had lost $24 billion in market cap and that the leaked results, while positive, looked more like a relative improvement than a decisive surprise. The reported numbers included a 42% reduction in the risk of cancer returning or death versus Keytruda, and a 38% reduction in the risk of cancer spreading, but the move was framed as a classic case of a stock that had already priced in a breakthrough.
Deckers reported record quarterly sales and better-than-expected adjusted earnings per share, but investors focused on softer guidance. The host said revenue rose 3.5% to nearly $1.5 billion, with Hoka up 6.8% and Ugg up 3.5%, while U.S. revenue slipped and international sales rose 9%. Management lifted EPS guidance but cut full-year sales guidance to $5.7 billion to $5.75 billion, which kept pressure on the shares near 52-week lows.
Norwegian Cruise Line was hit by a JPMorgan downgrade to underweight and a reduced price target of $11. The host said the bank’s main concern is 2027 demand and cost trends, especially because about 85% of Norwegian’s European itinerary customers come from the U.S. The question for investors is whether travel demand stays strong enough to support pricing if costs and consumer behavior shift.
Key takeaways
- The host said Moderna’s leak looked like a market-event trade, with expectations already so high that even positive phase 3 data was not enough to prevent a selloff.
- The host noted the leaked Moderna data showed a 42% relative reduction in recurrence or death versus Keytruda and a 38% reduction in spread risk.
- Deckers posted record quarterly revenue of nearly $1.5 billion, but the host said lower sales guidance mattered more than the EPS beat.
- The host said Deckers cut full-year sales guidance to $5.7 billion to $5.75 billion even as Hoka and Ugg still grew.
- JPMorgan’s downgrade of Norwegian Cruise Line reflects concern that 2027 demand and cost pressures could weigh on earnings, especially with heavy U.S. exposure to European cruises.
Notable quotes
“Moderna down about 5.5%. What analysts are say this this seem a classic case of buy the rumor. Sell the news”
“it reduced the risk of cancer returning or death by 42% compared to Keytruda a It also reduced the risk of cancer spreading to other parts of the body by 38%”
“The pressure continues for deckers stock down more than 6% offack of its results. It actually did post record sales, but its outlook from here is what is worrying investors”
“They're expecting now full year in the highe digits. That's from low double digits”
“They've lowered thisne to underweight reducing their pr target to $11. That's ahead of its earnings”
Topics
- mrna cancer vaccine trial leaks
- deckers earnings and guidance
- norwegian cruise line downgrade
- jpmorgan concerns
- stock market moves near 52-week lows
Companies and tickers mentioned
- MRNA
- DECK
- NCLH
- JPM
- Moderna
- Deckers Outdoor Corporation
- Norwegian Cruise Line Holdings
- JPMorgan Chase
Watch the episode
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Schwab Network
-
Jensen Huang Weighs Return as NVDA CEO; Risks & Rewards in 2027 CapEx Trade -
KG: "Shocked" by October Retail Sales; AI Chips Struggle as NVDA Drags -
NVDA Influence Beyond Tech: How Earnings Move VIX, Other Sectors -
The Big 3: SHOP, TMUS, S -
NVDA Earnings, Tighter AI Chip Restrictions to Test SPX Bulls -
How NVDA Earnings Will Move Wall Street; U.S. Tightens AI Chip Exports
Schwab Network, this episode and its artwork belong to their owners. Octagon is not affiliated with the show; this page is an independent summary.